• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Elicio Therapeutics, Inc. - Common Stock (NQ:ELTX)

    12.20 -1.35 (-9.96%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 146,600
    Open 13.52
    Bid (Size) 11.50 (200)
    Ask (Size) 13.00 (500)
    Prev. Close 13.55
    Today's Range 12.20 - 13.60
    52wk Range 4.695 - 14.93
    Shares Outstanding 29,798,399
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Elicio Therapeutics Reports Inducement Grants
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Inducement Grants
    From Elicio Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    +51.6%
    +51.6%
    1 Month
    +12.4%
    +12.4%
    3 Month
    +53.5%
    +53.5%
    6 Month
    +28.7%
    +28.7%
    1 Year
    +154.2%
    +154.2%

    More News

    Read More
    News headline image
    Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Inducement Grants
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Inducement Grants
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Inducement Grants
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Inducement Grants
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio (ELTX) Q2 Loss Beats Estimates ↗
    Via The Motley Fool
    News headline image
    Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Secures $10 Million in Financing
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
    From Elicio Therapeutics Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Elicio Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Elicio Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Elicio Therapeutics, Inc. - Common Stock trade on?
    Elicio Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Elicio Therapeutics, Inc. - Common Stock?
    The ticker symbol for Elicio Therapeutics, Inc. - Common Stock is ELTX on the Nasdaq Stock Market
    What is the current price of Elicio Therapeutics, Inc. - Common Stock?
    The current price of Elicio Therapeutics, Inc. - Common Stock is 12.20
    When was Elicio Therapeutics, Inc. - Common Stock last traded?
    The last trade of Elicio Therapeutics, Inc. - Common Stock was at 04/20/26 04:00 PM ET
    What is the market capitalization of Elicio Therapeutics, Inc. - Common Stock?
    The market capitalization of Elicio Therapeutics, Inc. - Common Stock is 363.54M
    How many shares of Elicio Therapeutics, Inc. - Common Stock are outstanding?
    Elicio Therapeutics, Inc. - Common Stock has 364M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.